← All trials
NCT00615186
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2008
- Primary completion
- Aug 1, 2013
- Completion date
- Dec 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 9
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Bradmer Pharmaceuticals Inc.Lead sponsor
- Duke UniversityOverall official - principal investigator
- University of NebraskaOverall official - principal investigator
- Cedars-Sinai Medical CenterOverall official - principal investigator
- Cornell UniversityOverall official - principal investigator
- University of South FloridaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.